2 results
Approved WMORecruiting
Primary: i) To determine the optimal 89Zr-DFO-REGN3767 protein dose and optimal PET imaging timepoint. ii) To evaluate the pharmacokinetics (PK) of 89Zr-DFO-REGN3767 by measuring standardized uptake value (SUV) on 89Zr-DFO-REGN3767 PET scans in…
Approved WMORecruiting
The aim of this study is to evaluate the difference in the fraction of patients that have disease progression within 6 months after applying 177Lu-PSMA RLT in patients with low volume, hormone sensitive metastatic prostate cancer. Ultimately, the…